Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mayo Clinic

Sites in Phoenix & Scottsdale, AZ

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
608
Shown on this page
12
Current sort
Recently updated
Campus scope
Mayo Clinic, Phoenix & Scottsdale, AZ
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Mayo Clinic, Phoenix & Scottsdale, AZ. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 529–540 of 608 matching trials with a site at Mayo Clinic, Phoenix & Scottsdale, AZ.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting No phase listed Observational Accepts healthy volunteers

Genetic Risk Estimations for Influencing Decision Making in Women at High Risk of Breast Cancer, GENRE 2 Study

NCT04474834
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Polygenic Risk Score
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 75 Years · Female only
Enrollment
737 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2029
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Evanston, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 22, 2026, 8:48 PM EDT
Recruiting Phase 3 Interventional

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

NCT06165341
Status at this site: Recruiting
View directory record Official record
Conditions
Alpha1-Antitrypsin Deficiency
Interventions
Fazirsiran Injection, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 22, 2026, 8:48 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

NCT01349322
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Standard fractionation whole breast irradiation, Hypofractionated whole breast irradiation, Concurrent boost, Sequential boost
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
2,354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
386
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 304 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 22, 2026, 8:48 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

NCT04416984
Site status not listed — check the official record
View directory record Official record
Conditions
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Interventions
ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide
Genetic · Biological · Drug
Lead sponsor
Allogene Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
24
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 22, 2026, 8:48 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

NCT06994806
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Tumor Malignancies
Interventions
KQB168, Pembrolizumab
Drug
Lead sponsor
Kumquat Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 22, 2026, 8:48 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

NCT06346067
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced or Metastatic NRAS-mutant Melanoma
Interventions
Naporafenib, Dacarbazine, Temozolomide, Trametinib
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
21
States / cities
Phoenix, Arizona • San Francisco, California • Englewood, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 22, 2026, 8:48 PM EDT
Recruiting Phase 3 Interventional

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

NCT05549297
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Melanoma
Interventions
Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice
Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
25
States / cities
Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 22, 2026, 8:48 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

NCT04430738
Site status not listed — check the official record
View directory record Official record
Conditions
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
Interventions
tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 22, 2026, 8:48 PM EDT
Recruiting Not applicable Interventional

Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

NCT02958462
Status at this site: Recruiting
View directory record Official record
Conditions
Myeloid Malignancy, Inherited Bone Marrow Failure Syndrome, Clonal Expansion, Cytopenia, Bone Marrow Failure Syndrome, Clonal Cytopenia of Undetermined Significance, Clonal Hematopoiesis of Indeterminate Potential, Hematologic Neoplasms, Hematopoietic and Lymphatic System Neoplasm, Hereditary Neoplastic Syndrome, Idiopathic Cytopenia of Undetermined Significance, Idiopathic Dysplasia of Uncertain Significance, Low Risk Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Punch Biopsy, Buccal Swab, Clinical Evaluation, Genetic Counseling, Quality-of-Life Assessment, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2035
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 22, 2026, 8:48 PM EDT
Recruiting Phase 2 Interventional

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06356571
Status at this site: Recruiting
View directory record Official record
Conditions
Plasma Cell Myeloma Refractory
Interventions
Isatuximab SC-OBDS, Montelukast, Dexamethasone, Acetaminophen, Diphenhydramine, Methylprednisolone, Carfilzomib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Los Angeles, California • West Hollywood, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 22, 2026, 8:48 PM EDT
Recruiting Phase 2 Interventional

BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

NCT06854003
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Mantle Cell Lymphoma, Lymphoma
Interventions
Bendamustine, Rituximab, Cytarabine, Zanubrutinib, Sonrotoclax
Drug
Lead sponsor
Christine Ryan
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2039
U.S. locations
7
States / cities
Phoenix, Arizona • Boston, Massachusetts • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 22, 2026, 8:48 PM EDT
Active, not recruiting No phase listed Observational

Long Term Followup of Patients Enrolled in MC1137, BEAUTY Study

NCT05703399
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Biospecimen Collection, Questionnaire Administration
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 22, 2026, 8:48 PM EDT

About this Mayo Clinic institution page

What this page lists
ClinicalTrials.gov records that list Mayo Clinic in Phoenix & Scottsdale, AZ as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Mayo Clinic at any site, browse by condition, or browse by U.S. city.